FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

Uğur Şahin(Johannes Gutenberg University Mainz), S. Al-Batran(Krankenhaus Nordwest), Ahsan M. Arozullah(Astellas Pharma (United States)), Igor Bondarenko(Dnipro State Medical University), Assen Dudov(Acibadem City Clinic), Christoph Huber(University Hospital of Geneva), Martin Schüler(German Cancer Research Center), Karl Dhaene, Ihor Vynnychenko(Sumy State University), I. Bazin(Russian Cancer Research Center NN Blokhin), Kai Wiechen(University of Applied Sciences Worms), Andriy Rusyn, J.W. Park(Astellas Pharma (United States)), Daniel Maurus(MerLion Pharma (Germany)), Georgy M. Manikhas(City Clinical Oncology Center), Ö. Türeci(BioNTech (Germany)), Florian Lordick(Leipzig University), Bohuslav Melichar(Palacký University Olomouc)
Annals of Oncology
February 21, 2021
10.1016/j.annonc.2021.02.005
Cited by 357

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k